| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| | 10-K | 10-K | 10-K |
| ASSETS | | | |
| Current assets: | | | |
| Cash | 7.9 | 1.8 | 0.0 |
| Prepaid expenses and other current assets | 0.2 | 0.1 | 0.1 |
| Total current assets | 8.2 | 2.0 | 0.8 |
| Property and equipment, net | 0.0 | 0.0 | 0.0 |
| Total assets | 8.2 | 2.0 | 0.8 |
| |
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | | | |
| Current liabilities: | | | |
| Accounts payable and accrued expenses | 4.2 | 1.5 | 0.9 |
| Total current liabilities | 4.2 | 3.8 | 0.9 |
| |
| COMMITMENTS AND CONTINGENCIES | | | |
| Stockholders' equity (deficit): | | | |
| Preferred stock, $0.001 par value; 20,000,000 shares authorized; zero shares issued and outstanding | | | |
| Common stock | 0.0 | 0.0 | 0.0 |
| Additional paid-in capital | 45.5 | 14.2 | 3.6 |
| Accumulated deficit | -41.5 | -14.5 | -3.6 |
| Accumulated other comprehensive income (loss) | -0.1 | -0.1 | 0.0 |
| Total Scopus BioPharma Inc. stockholders' deficit | 4.0 | -1.8 | -0.1 |
| Total liabilities and stockholders' deficit | 8.2 | 2.0 | 0.8 |